Get started
Author

Aleksandra Leśniak

Observed names: A. Leśniak, Aleksandra Lesniak, Lesniak, Aleksandra, Leśniak, Aleksandra
OpenAlex ID: A5055075238
Anti-androgen hormonal therapy for cancer and other diseases
2019 · Sebastian Student, Tomasz Hejmo, et al. · European Journal of Pharmacology · 59
PDF
Safety and Feasibility of Radiation Therapy Combined with CDK 4/6 Inhibitors in the Management of Advanced Breast Cancer
2023 · Marcin Kubeczko, Dorota Gabryś, et al. · Cancers · 27
PDF
Brain metastases of sarcoma: a rare phenomenon in rare tumours
2023 · Wiktoria Jędrys, Aleksandra Leśniak, et al. · Journal of Cancer Research and Clinical Oncology · 14
PDF
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxane
2026 · Marcin Kubeczko, Sandra Cobo, et al. · npj Breast Cancer · 3
PDF
Tailoring advanced breast cancer treatment after cyclin-dependent kinase 4/6 inhibitors progression - real-world data analysis
2024 · Marcin Kubeczko, Anna Polakiewicz-Gilowska, et al. · Frontiers in Oncology · 2
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
2025 · Marcin Kubeczko, Andrea d’Amico, et al. · Breast Cancer Research · 1
Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors
2026 · Marcin Kubeczko, Anna Polakiewicz-Gilowska, et al. · BMC Cancer
Additional file 1 of Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors
2026 · Kubeczko, Marcin, Polakiewicz-Gilowska, Anna, et al. · Figshare
Deciphering the role of Ki67: prognostic insights in advanced breast cancer therapy with Cyclin-dependent kinase 4/6 inhibitors
2026 · Kubeczko, Marcin, Polakiewicz-Gilowska, Anna, et al. · Figshare
Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
2026 · Kubeczko, Marcin, d’Amico, Andrea, et al. · Figshare
Additional file 1 of Prognostic value of baseline FDG PET/CT in HER2-positive metastatic breast cancer treated with first-line trastuzumab, pertuzumab, and docetaxel
2026 · Kubeczko, Marcin, d’Amico, Andrea, et al. · Figshare
Abstract P4-12-07: Cyclin-dependent kinase 4/6 inhibitors dose reduction in patients with endocrine resistant advanced breast cancer experiencing early disease progression
2025 · Marcin Kubeczko, Anna Polakiewicz-Gilowska, et al. · Clinical Cancer Research
Positron-emission tomography utility for progression-free survival prediction in HER2-positive advanced breast cancer patients treated with pertuzumab, trastuzumab, and docetaxel.
2025 · Marcin Kubeczko, Andrea d'Amico, et al. · Journal of Clinical Oncology
P211: Impact of Pembrolizumab Addition on the Predictive Value of Metabolic Activity for Pathologic Complete Response in Breast Cancer
2025 · M. Kubeczko, A. d'Amico, et al. · The Breast
Abstract PO1-05-01: Cyclin-dependent Kinase 4/6 Inhibitors Combined with Radiotherapy in the Management of Brain Metastases in HR-positive/HER2-negative Breast Cancer Patients
2024 · Marcin Kubeczko, Dorota Gabryś, et al. · Cancer Research
230P HER2-low status in advanced breast cancer patients treated with CDK4/6 inhibitors: Is it predictive of outcome?
2024 · M. Kubeczko, A. Polakiewicz-Gilowska, et al. · ESMO Open
PDF
Abstract P2-12-07: Fdg PET/CT early response prediction for triple negative breast cancer neoadjuvant chemotherapy with addition of carboplatin
2022 · Marcin Kubeczko, Anna Michalik, et al. · Cancer Research
Abstract PS15-09: Adverse events in breast cancer patients treated with concurrent or sequential radiation therapy and CDK 4/6 inhibitors in metastatic setting
2021 · Marcin Kubeczko, Agnieszka Badora-Rybicka, et al. · Cancer Research
Defining a SUV decrease cut-off in PET/CT response monitoring after one cycle of preoperative breast cancer chemotherapy
2019 · M. Kubeczko, K. Świderska, et al. · Annals of Oncology
PDF
The efficacy of preoperative breast cancer chemotherapy without anti-HER2-targeted treatment: Single center experience in setting of no reimbursement in Poland (2011-2015)
2019 · A. Badora-Rybicka, A. Polakiewicz-Gilowska, et al. · Annals of Oncology
Czy lekarze rodzinni u progu kariery mają powody do zmartwień
2015 · Anna Wawrzyniak, Natalia Więcław, et al. · Forum Medycyny Rodzinnej
C154: Clinicopathological prognostic factors for patients' survival for mediastinal primary malignant germ cell tumor
2014 · E. Nowara, K. Drosik-Rutowicz, et al. · European Urology Supplements
Large cell carcinoma of the lung and squamous cell carcinoma of the oropharynx presenting as uveitis.
2009 · Aleksandra Lesniak, William G Hodge · PubMed
Works count: 23
Citation count: 106
H-index: 3
I10-index: 3
Year
Topic
Type